Physician profile
Charles Galea
NPI 1174517502
$17,410.38
in general payments reported to CMS, 2019-2025
42 companies · $2,485 in 2025
The $2,485 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,021 · 2020: $2,152 · 2021: $2,633 · 2022: $2,869 · 2023: $2,173 · 2024: $2,078 · 2025: $2,485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,509 · Education: $227.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,509.15 |
| Education | $226.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,888.50 | 2019-2025 | Tavneos, Krystexxa, Evenity |
| Abbvie INC. | $2,087.29 | 2019-2025 | |
| Ucb, INC. | $2,004.69 | 2019-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $1,929.17 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Horizon Therapeutics Plc | $875.63 | 2019-2023 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $722.77 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $712.19 | 2020-2025 | Acthar |
| Glaxosmithkline, LLC. | $676.07 | 2019-2025 | Benlysta |
| Genentech USA, INC. | $577.58 | 2019-2025 | Actemra |
| Pfizer INC. | $537.78 | 2019-2025 | |
| Aurinia Pharma U.S., INC. | $477.75 | 2021-2025 | Lupkynis |
| Genzyme Corporation | $468.53 | 2019-2025 | |
| Radius Health, INC. | $463.98 | 2019-2025 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $418.58 | 2019-2025 | Ofev |
| Lilly USA, LLC | $413.96 | 2019-2024 | Taltz |
Show all 41 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Galea listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.